Cargando…

Pembrolizumab on pre-existing inclusion body myositis: a case report

BACKGROUND: Cases of exacerbation of pre-existing neuromuscular diseases induced by immune checkpoint inhibitors (ICIs) have rarely been reported because patients with autoimmune diseases have generally been excluded from ICI therapy due to the increased risk of exacerbation. We describe the first c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uchio, Naohiro, Unuma, Atsushi, Kakumoto, Toshiyuki, Osaki, Masao, Zenke, Yoshitaka, Sakuta, Kenichi, Kubota, Akatsuki, Uesaka, Yoshikazu, Toda, Tatsushi, Shimizu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493364/ https://www.ncbi.nlm.nih.gov/pubmed/32944686 http://dx.doi.org/10.1186/s41927-020-00144-5

Ejemplares similares

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology
por: Uchio, Naohiro, et al.
Publicado: (2018)

Longus Colli Tendinitis in a Patient Presenting with Neck Pain and Acute Systemic Inflammation
por: Uchida, Takayasu, et al.
Publicado: (2018)

Muscle Transcriptomics Shows Overexpression of Cadherin 1 in Inclusion Body Myositis
por: Ikenaga, Chiseko, et al.
Publicado: (2022)

Progressive Supranuclear Palsy with Wall-Eyed Bilateral Internuclear Ophthalmoplegia Syndrome: Authors' Second Case
por: Matsumoto, Hideyuki, et al.
Publicado: (2019)

Cranial Nerve Involvement and Dysautonomia in Post-COVID-19 Guillain-Barré Syndrome
por: Kakumoto, Toshiyuki, et al.
Publicado: (2021)

Paraspinal muscle involvement in pembrolizumab-associated myositis
por: Nosaki, Yasunobu, et al.
Publicado: (2020)

Neurofilament light chain levels in cerebrospinal fluid as a sensitive biomarker for cerebral adrenoleukodystrophy
por: Kakumoto, Toshiyuki, et al.
Publicado: (2023)

Long-term survival from progressive multifocal leukoencephalopathy in living-donor liver transplant recipient with preformed donor-specific antibody
por: Egashira, Shuhei, et al.
Publicado: (2023)

Update in inclusion body myositis
por: Machado, Pedro, et al.
Publicado: (2013)

Genetics in inclusion body myositis
por: Rothwell, Simon, et al.
Publicado: (2017)

The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
por: Edigin, Ehizogie, et al.
Publicado: (2020)

Copper Deficiency in Wilson's Disease with a Normal Zinc Value
por: Ueda, Masayuki, et al.
Publicado: (2022)

Detecting dysphagia in inclusion body myositis
por: Cox, F. M., et al.
Publicado: (2009)

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

Pembrolizumab‐induced myasthenia gravis with myositis in a patient with lung cancer
por: Hibino, Makoto, et al.
Publicado: (2018)

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm
por: Haddox, C. L., et al.
Publicado: (2017)

Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report
por: Sakoh, Takashi, et al.
Publicado: (2019)

The effect of immunosuppressive therapy on cardiac involvements in anti‐mitochondrial antibody‐positive myositis
por: Bujo, Satoshi, et al.
Publicado: (2022)

Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
por: Huh, So-Young, et al.
Publicado: (2018)

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Inclusion body myositis--a case report.
por: Park, S. H., et al.
Publicado: (1996)

Inclusion-Body Myositis Associated with Alzheimer's Disease
por: Levacic, Danijela, et al.
Publicado: (2013)

Inclusion body myositis associated with Sjögren’s syndrome
por: Misterska-Skóra, Maria, et al.
Publicado: (2012)

Proteomic study of sporadic inclusion body myositis
por: Li, Ke, et al.
Publicado: (2014)

Ongoing Developments in Sporadic Inclusion Body Myositis
por: Machado, Pedro M., et al.
Publicado: (2014)

17. Inclusion body myositis associated with SLE
por: Jones, Catrin M, et al.
Publicado: (2018)

Immune and myodegenerative pathomechanisms in inclusion body myositis
por: Keller, Christian W., et al.
Publicado: (2017)

Survival and associated comorbidities in inclusion body myositis
por: Naddaf, Elie, et al.
Publicado: (2021)

Dysphagia as the Presenting Symptom for Inclusion Body Myositis
por: Esteban, Marcus Juan, et al.
Publicado: (2021)

Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy
por: Kadoya, Masato, et al.
Publicado: (2016)

Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Todo, Maki, et al.
Publicado: (2019)

Early development of pembrolizumab‐induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma
por: Jang, Soo Yeon, et al.
Publicado: (2022)

Sporadic inclusion body myositis: the genetic contributions to the pathogenesis
por: Gang, Qiang, et al.
Publicado: (2014)

Mitochondrial and inflammatory changes in sporadic inclusion body myositis
por: Rygiel, Karolina A., et al.
Publicado: (2015)

Emerging therapeutic options for sporadic inclusion body myositis
por: Alfano, Lindsay N, et al.
Publicado: (2015)

Inclusion body myositis – pathomechanism and lessons from genetics
por: Murnyák, Balázs, et al.
Publicado: (2015)

Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis
por: de Camargo, Leonardo Valente, et al.
Publicado: (2018)

CYLD dysregulation in pathogenesis of sporadic inclusion body myositis
por: Yamashita, Satoshi, et al.
Publicado: (2019)

Inclusion body myositis in a patient with rheumatoid arthritis
por: Tariq, Mohammad, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5qd4qlj921lgpa694q5p9mcbc3